These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12577190)

  • 1. The effects of alendronate in postmenopausal women with osteoporosis.
    Yaniv I
    Osteoporos Int; 2003 Jan; 14(1):90-1. PubMed ID: 12577190
    [No Abstract]   [Full Text] [Related]  

  • 2. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of special studies with alendronate.
    McClung M
    Int J Clin Pract Suppl; 1999 Apr; 101():67-72. PubMed ID: 12669743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy.
    Palomba S; Orio F; Russo T; Colao A; Lombardi G; Zullo F
    Fertil Steril; 2004 Feb; 81(2):476-8. PubMed ID: 14967398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
    Miller PD
    N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714279
    [No Abstract]   [Full Text] [Related]  

  • 7. Alendronate in the treatment of postmenopausal osteoporosis.
    Hosking DJ; Favus M; Yates AJ
    Int J Clin Pract Suppl; 1999 Apr; 101():27-35. PubMed ID: 12669738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
    J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate.
    Hamdy RC
    South Med J; 1999 Nov; 92(11):1118-20. PubMed ID: 10586845
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
    Cheng ZQ; Yin W; Fan JY; Ma TJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F; Rodoplu M
    Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of Fosamax sustains or continues increases in bone density.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Apr; 15(8):9-10, 12. PubMed ID: 15112661
    [No Abstract]   [Full Text] [Related]  

  • 16. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
    Ott SM
    N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250064
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year.
    Musialik J; Petelenz M; Gonciarz Z
    Scand J Gastroenterol; 2005 Jul; 40(7):873-4. PubMed ID: 16109666
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P; Stancíková M; Letkovská A; Rovenský J
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination and sequential therapy for osteoporosis.
    Heaney RP; Recker RR
    N Engl J Med; 2005 Aug; 353(6):624-5. PubMed ID: 16093472
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.
    Eviö S; Tarkkila L; Sorsa T; Furuholm J; Välimäki MJ; Ylikorkala O; Tiitinen A; Meurman JH
    Oral Dis; 2006 Mar; 12(2):187-93. PubMed ID: 16476042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.